Angelika Dobrieva

Hemogenyx Pharmaceuticals · Case study

Redesigning a listed biotech website for two opposite visitors

Hemogenyx Pharmaceuticals develops therapies for blood and immune system diseases. It is publicly listed, so its website is both where the science gets explained and where shareholders go for filings.

Role
UX/UI designer — end to end
Year
2023
Client
Hemogenyx Pharmaceuticals — New York biotech, publicly listed
My scope
Audit · Information architecture · Wireframes · Navigation · Visual concepts · Responsive UI · Handoff

01 — From One Audience to Two

Designing one site for opposite intentions

Two kinds of visitor arrive at the same homepage wanting opposite things, and the old navigation was built for neither.

Two arrivals

  • InvestorA document
  • ReaderAn explanation

An investor already knows which document they want and resents every click between them and the PDF. A scientific or general reader knows nothing yet, and needs the clinical need explained before the technology means anything at all.

Before

  • One menu
  • Both audiences
  • Neither served

I set three goals and defended their order. A new visual language applied to the old architecture would only have made the same problem better-looking.

The order I argued for

  • Structure
  • Navigation
  • Visual

Designed for

  • Investor
  • Scientific reader
  • General reader

02 — From a Grown Site to a Mapped One

Separating pages, documents and other companies' websites

The site had grown rather than been designed: content spread across a large number of pages, some redundant, some empty, and no reliable map of what was actually there.

Three destinations that were linked identically

  • Internal pageStays on the site
  • PDF documentDownloads
  • External linkLeaves for LSE, ComputerShare

Where a click lands changes what the visitor should expect, so the sitemap distinguishes the three rather than drawing them as one kind of thing.

The rebuilt hierarchy

  • Site
    • Header
      • News
      • Technology
      • Pipeline
      • Investors
      • About
    • Footer
      • Join us
      • Contacts
      • Privacy policy

Investor material

  • Eleven destinations
  • One Investors section
  • Governance
  • Advisers
  • Registrar
  • Shareholder information
  • Share data
  • Annual and half-year reports

Removed

  • Empty pages
  • Duplicate pages
  • Eleven separate investor destinations


04 — From Stock Imagery to a Subject

Imagery that argues for the science instead of decorating it

Before

  • Dense regulatory content
  • Generic stock photography
A visual language working against the science

Selection

  • Six directions
  • One chosen
  • Applied everywhere

Six directions tested different balances of scientific imagery, typographic scale and density. The chosen one is minimal and light.

The system

  • Visual system
    • Near-white backgrounds
    • Strong sans-serif display scale
    • Brand red
      • Links · Dates · Tags · Primary actions
    • One motif
      • Soft-focus 3D blood-cell forms
      • Hero and page-header washes only

The stock photography came out. The motif is used sparingly enough that it reads as subject matter rather than as decoration, and the brand red is held back so that it still means something when it appears.

The same system carries

  • Tables for share data
  • A timeline for company history
  • Accordions for step-by-step science
  • Oversized page titles

05 — From Three Widths to Three Decisions

Deciding what breaks before it breaks

Three widths across the whole site. Three things were worth deciding rather than discovering.

What had to be decided

  • SidebarNo room beside the content
  • Share tablesCannot be wide
  • Document listHas to stay usable on a phone

On mobile the fixed sidebar becomes a horizontal, swipeable section switcher, so the same orientation cue survives the small screen instead of collapsing into a hamburger.

Designed for

  • Desktop
  • Tablet
  • Mobile

Status

  • Delivered end to end
  • Structure before navigation before visual
  • Design outcomes, no post-launch analytics in scope
Next case
BAIT Biotechnology